Development and Validation of the Migraine-Specific Quality of Life Questionnaire

Priti Jhingran PhD

Corresponding Author

Priti Jhingran PhD

From Glaxo Wellcome Inc, Research Triangle Park, NC (Drs. Jhingran, Osterhaus and Miller) and

Address all correspondence to Dr. Priti Jhingran, Glaxo Wellcome Inc, Five Moore Drive, Research Triangle Park, NC 27709.Search for more papers by this author
Jane T. Osterhaus PhD

Jane T. Osterhaus PhD

From Glaxo Wellcome Inc, Research Triangle Park, NC (Drs. Jhingran, Osterhaus and Miller) and

Search for more papers by this author
David W. Miller PhD

David W. Miller PhD

From Glaxo Wellcome Inc, Research Triangle Park, NC (Drs. Jhingran, Osterhaus and Miller) and

Search for more papers by this author
Jeffrey T. Lee PharmD

Jeffrey T. Lee PharmD

Advanced Health Outcomes, Inc (Dr. Lee), Research Triangle Park, NC and

Search for more papers by this author
Leonard Kirchdoerfer PhD

Leonard Kirchdoerfer PhD

Health Economics, Genentech, San Francisco, Calif (Dr. Kirchdoefer).

Search for more papers by this author
First published: 05 June 2003
Citations: 170

Abstract

This paper describes the development and validation of a migraine-specific quality-of-life instrument that is capable of measuring health-related quality-of-life impairments attributed to migraine. Item selection, item reduction, and pretesting and finalization of items during the instrument development phase resulted in a total of 16 questions which were incorporated into the Migraine-Specific Quality of Life Questionnaire (Version 1:0) (©1992 Glaxo Wellcome Inc). Three meaningful dimensions were hypothesized: Role Function-Restrictive, Role Function-Preventive, and Emotional Function. In the instrument validation phase, the Migraine-Specific Quality of Life Questionnaire was mailed to 1109 migraine patients, providing a response rate of 45% (n=458). Initial psychometric evaluation of the questionnaire indicated that it possessed adequate reliability with Cronbach's alpha for the three dimensions ranging between 0.70 to 0.85. The Migraine-Specific Quality of Life Questionnaire possessed adequate content and criterion validity. All but three items satisfied the test of construct validity. In conclusion, the Migraine-Specific Quality of Life Questionnaire has acceptable psychometric properties and can be used to estimate the effect of migraine and its treatment on the patient's health-related quality of life.